Book Description
Review of the anti-drug certification process : hearing before the Committee on Foreign Relations, United States Senate, One Hundred Seventh Congress, first session, March 1, 2001.
Author : United States. Congress
Publisher : Createspace Independent Publishing Platform
Page : 54 pages
File Size : 35,3 MB
Release : 2018-01-05
Category :
ISBN : 9781983503290
Review of the anti-drug certification process : hearing before the Committee on Foreign Relations, United States Senate, One Hundred Seventh Congress, first session, March 1, 2001.
Author : United States. Congress. Senate. Committee on Foreign Relations
Publisher :
Page : 56 pages
File Size : 29,56 MB
Release : 2001
Category : Political Science
ISBN :
Author : United States. Congress. Senate. Committee on Foreign Relations
Publisher :
Page : 49 pages
File Size : 44,82 MB
Release : 2001
Category : Drug abuse
ISBN :
Author :
Publisher :
Page : pages
File Size : 14,49 MB
Release : 2001*
Category :
ISBN :
Author : National Academies of Sciences, Engineering, and Medicine
Publisher : National Academies Press
Page : 483 pages
File Size : 49,23 MB
Release : 2017-09-28
Category : Medical
ISBN : 0309459575
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author : Drug Strategies (Organization)
Publisher :
Page : 12 pages
File Size : 32,18 MB
Release : 1998
Category : Drug control
ISBN :
Author : United States. Congress. Senate. Caucus on International Narcotics Control
Publisher :
Page : 130 pages
File Size : 14,82 MB
Release : 2000
Category : Political Science
ISBN :
Author : United States. General Accounting Office
Publisher :
Page : 48 pages
File Size : 18,81 MB
Release : 1999
Category : Drug abuse
ISBN :
Author : United States. Congress. House. Committee on Foreign Affairs
Publisher :
Page : 424 pages
File Size : 29,51 MB
Release : 1990
Category : Drug control
ISBN :
Author :
Publisher :
Page : 0 pages
File Size : 24,88 MB
Release : 2000
Category :
ISBN :
An important element of U.S. international narcotics control strategy involves the threat of, or application of, sanctions against major illicit drug producing or trafficking nations. These range from suspension of U.S. foreign assistance and preferential trade benefits to curtailment of air transportation. Sections 489 and 490 of the Foreign Assistance Act of 1961, as amended, require the President to submit to Congress by March 1 each year a list of major illicit drug producing and transiting countries that he has certified as fully cooperative and therefore fully eligible to receive U.S. foreign aid, without discretionary imposition of any concomitant economic and trade sanctions. This sets in motion a 30-calendar-day review process in which Congress can disapprove the President's certification and stop U.S. foreign aid and other benefits from going to specific countries. This report provides answers to frequently asked questions about the certification process and the requirements for Congress to disapprove a drug certification by the President.